Changes in glomerular filtration rate in patients with body mass index ≥35 kg/m2 treated with metabolic and bariatric surgery versus GLP-1 agonist at 1-year follow-up.

IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM Obesity Science & Practice Pub Date : 2024-08-10 eCollection Date: 2024-08-01 DOI:10.1002/osp4.782
Diana Cristina Henao-Carrillo, Mayra Alejandra Jurado-Florez, Óscar Mauricio Muñoz
{"title":"Changes in glomerular filtration rate in patients with body mass index ≥35 kg/m<sup>2</sup> treated with metabolic and bariatric surgery versus GLP-1 agonist at 1-year follow-up.","authors":"Diana Cristina Henao-Carrillo, Mayra Alejandra Jurado-Florez, Óscar Mauricio Muñoz","doi":"10.1002/osp4.782","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Metabolic and bariatric surgery (MBS) reduces glomerular hyperfiltration. The renoprotective effects of GLP-1 analogs were derived from clinical studies in type 2 diabetes (T2D). The objective of this study was to evaluate the changes in glomerular filtration rate (GFR) over time associated with weight loss in patients with a BMI ≥ 35 kg/m<sup>2</sup> treated with liraglutide compared with patients treated with MBS.</p><p><strong>Methods: </strong>A longitudinal study derived from a retrospective cohort of patients with BMI ≥ 35 kg/m<sup>2</sup> treated with either MBS or liraglutide 3 mg/day, with follow-up ≥1 year. Clinical variables, baseline GFR, and 1-year GFR were analyzed. A generalized estimating equation (GEE) model was used to compare changes in GFR between both groups while controlling for confounding variables.</p><p><strong>Results: </strong>A total of 159 patients were included in the analysis. Of these, 129 patients underwent MBS (median age 60.5 years [IQR 51.8-66.6], body mass index (BMI) 40.9 kg/m2 [IQR 0.68-0.89]), and 30 patients were treated with liraglutide (median age 56 years [IQR 46-62], BMI 37.4 kg/m<sup>2</sup> [IQR 0.69-0.93]). No difference in baseline GFR or at 12 months of follow-up was found between the two interventions. GEE analysis revealed an increase of 0.32 mL/min/1.73 m<sup>2</sup> per month of follow-up. Factors associated with a greater increase in GFR were the percentage total weight loss (%TWL) (0.12 mL/min/1.73 m<sup>2</sup>, <i>p</i> = 0.023) and baseline GFR (0.69 mL/min/1.73 m<sup>2</sup>, <i>p</i> > 0.001) for both interventions, independent of a history of T2D.</p><p><strong>Conclusion: </strong>In patients with BMI ≥ 35 kg/m<sup>2</sup>, changes in GFR are related to %TWL and baseline GFR, regardless of the presence of diabetes or the type of intervention used.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316517/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Science & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/osp4.782","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Metabolic and bariatric surgery (MBS) reduces glomerular hyperfiltration. The renoprotective effects of GLP-1 analogs were derived from clinical studies in type 2 diabetes (T2D). The objective of this study was to evaluate the changes in glomerular filtration rate (GFR) over time associated with weight loss in patients with a BMI ≥ 35 kg/m2 treated with liraglutide compared with patients treated with MBS.

Methods: A longitudinal study derived from a retrospective cohort of patients with BMI ≥ 35 kg/m2 treated with either MBS or liraglutide 3 mg/day, with follow-up ≥1 year. Clinical variables, baseline GFR, and 1-year GFR were analyzed. A generalized estimating equation (GEE) model was used to compare changes in GFR between both groups while controlling for confounding variables.

Results: A total of 159 patients were included in the analysis. Of these, 129 patients underwent MBS (median age 60.5 years [IQR 51.8-66.6], body mass index (BMI) 40.9 kg/m2 [IQR 0.68-0.89]), and 30 patients were treated with liraglutide (median age 56 years [IQR 46-62], BMI 37.4 kg/m2 [IQR 0.69-0.93]). No difference in baseline GFR or at 12 months of follow-up was found between the two interventions. GEE analysis revealed an increase of 0.32 mL/min/1.73 m2 per month of follow-up. Factors associated with a greater increase in GFR were the percentage total weight loss (%TWL) (0.12 mL/min/1.73 m2, p = 0.023) and baseline GFR (0.69 mL/min/1.73 m2, p > 0.001) for both interventions, independent of a history of T2D.

Conclusion: In patients with BMI ≥ 35 kg/m2, changes in GFR are related to %TWL and baseline GFR, regardless of the presence of diabetes or the type of intervention used.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
体重指数≥35 kg/m2患者接受代谢和减肥手术与 GLP-1 激动剂治疗后 1 年随访期间肾小球滤过率的变化。
背景:代谢和减肥手术(MBS)可降低肾小球高滤过率。GLP-1 类似物对肾脏的保护作用来自于对 2 型糖尿病(T2D)的临床研究。本研究的目的是评估体重指数(BMI)≥ 35 kg/m2、接受利拉鲁肽治疗的患者与接受MBS治疗的患者相比,肾小球滤过率(GFR)随时间推移发生的变化:这是一项纵向研究,研究对象是BMI≥35 kg/m2、接受MBS或利拉鲁肽3 mg/天治疗的患者,随访时间≥1年。对临床变量、基线 GFR 和 1 年 GFR 进行了分析。采用广义估计方程(GEE)模型比较两组患者的 GFR 变化,同时控制混杂变量:结果:共有 159 名患者被纳入分析。其中,129 名患者接受了 MBS 治疗(中位年龄 60.5 岁 [IQR:51.8-66.6],体重指数 (BMI):40.9 kg/m2 [IQR:0.68-0.89]),30 名患者接受了利拉鲁肽治疗(中位年龄 56 岁 [IQR:46-62],体重指数 (BMI):37.4 kg/m2 [IQR:0.69-0.93])。两种干预方法的基线 GFR 和随访 12 个月时的 GFR 均无差异。GEE 分析显示,随访每月的 GFR 增加了 0.32 mL/min/1.73 m2。在两种干预方法中,与 GFR 增加幅度较大相关的因素是总减重百分比(%TWL)(0.12 mL/min/1.73 m2,p = 0.023)和基线 GFR(0.69 mL/min/1.73 m2,p > 0.001),与 T2D 病史无关:结论:对于体重指数(BMI)≥ 35 kg/m2的患者,无论是否患有糖尿病或采用何种干预措施,其肾小球滤过率的变化都与TWL%和基线肾小球滤过率有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Obesity Science & Practice
Obesity Science & Practice ENDOCRINOLOGY & METABOLISM-
CiteScore
4.20
自引率
4.50%
发文量
73
审稿时长
29 weeks
期刊最新文献
Predictors of ongoing attendance at an Australian publicly funded specialist obesity service. The impact of weight self-stigma on weight-loss treatment engagement and outcome. Optimizing muscle preservation during weight loss in patients with cirrhosis: A pilot study comparing continuous energy restriction to alternate-day modified fasting for weight loss in patients with obesity and non-alcoholic cirrhosis of the liver. Patient, facility, and environmental factors associated with obesity treatment in US Veterans. Metabolic obesity phenotypes and thyroid cancer risk: A systematic exploration of the evidence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1